Holly Bernardini, DO
Family Medicine · Charlotte, NCNPI 1205883113
Payments from drug & device makers
Across 85 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$137
- Pfizer$128
- Johnson & Johnson$107
- Lilly USA, LLC$92
- AstraZeneca$80
- Boehringer Ingelheim$80
- plus $562 from 19 others
What the payments were for
- Food & beverage$1,186100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $137 |
| Pfizer | 9 | $128 |
| Johnson & Johnson | 6 | $107 |
| Lilly USA, LLC | 7 | $92 |
| AstraZeneca | 6 | $80 |
| Boehringer Ingelheim | 6 | $80 |
| AbbVie | 6 | $78 |
| Novo Nordisk | 5 | $66 |
| Eisai Inc. | 4 | $53 |
| Astellas Pharma US Inc | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Amarin Pharma, Inc. | 2 | $30 |
| GSK | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Merck | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Neos Therapeutics, LP | 1 | $21 |
| Urovant Sciences Inc | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
How this compares
$1,186 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,653 | $529,216 |
| IngrezzaValbenazine Tosylate | 54 | $212,208 |
| TrulicityDulaglutide | 239 | $159,441 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $108,636 |
| JardianceEmpagliflozin | 297 | $97,336 |
| XareltoRivaroxaban | 277 | $79,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $68,225 |
| LinzessLinaclotide | 113 | $57,432 |
| Invega SustennaPaliperidone Palmitate | 16 | $45,586 |
| MounjaroTirzepatide | 45 | $44,885 |
| XifaxanRifaximin | 21 | $43,929 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $42,263 |
| Divalproex Sodium | 655 | $40,198 |
| NuedextaDextromethorphan Hbr/Quinidine | 40 | $35,704 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $34,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $529,2161,653 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $92 | $204,326284 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $80 | $135,603375 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $107 | $125,586293 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $28 | $114,093245 claims |
| AbbVieLinzess, Restasis | $78 | $86,416180 claims |
| AstraZenecaFarxiga | $80 | $34,21591 claims |
| Novo NordiskOzempic | $66 | $30,58530 claims |
| NovartisEntresto | $137 | $28,16691 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $20,42784 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $15,2691,077 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Charlotte
- George RaadCharlotte$7.7M
- Steven BauerCharlotte$2.7M
- Melissa JonesCharlotte$1.8M
- Laura LuptonCharlotte$811K
- Kevin SodenCharlotte$558K
- Joseph KonenCharlotte$322K
- Thomas BarringerCharlotte$305K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Jewell CarrCharlotte$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.